Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9057558 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL9973633 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL9055032 | 0.98 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL24179519 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL27987174 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL990336 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL8059750 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL22081089 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL7352304 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL28904441 | 0.81 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724251-A1 | IONIC HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | Covestro Intellectual Property GmbH & Co. KG (DE) | 2020-10-21 | — | — | EP | claimed |
| EP-3097091-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2015112445-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | claimed |
| WO-2025047373-A1 | ELECTROLYTIC CAPACITOR AND LIQUID COMPONENT FOR ELECTROLYTIC CAPACITORS | パナソニックＩＰマネジメント株式会社 | 2025-03-06 | — | — | WO | disclosed |
| US-20240393298-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | PHENOMENEX, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4359786-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | Phenomenex, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-111755749-B | Electrolyte additive, electrolyte and lithium ion secondary battery comprising same | 株式会社村田制作所 | 2024-02-06 | — | — | CN | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20060199854-A1 | Process for the preparation of n-substituted 2-cyanopyrrolidines | NOVARTIS AG | 2006-09-07 | — | — | US | disclosed |
| CN-1774420-A | Process for preparing N-substituted 2-cyanopyrrolidines | NOVARTIS AG (CH) | 2006-05-17 | — | — | CN | disclosed |
| CN-1737059-A | Moisture-curable polyurethane resin composition | NIPPON POLYURETHANE KOGYO KK (JP) | 2006-02-22 | — | — | CN | disclosed |
| EP-1620396-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092127-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| WO-1996038465-A1 | ALKYL 2β-MORPHOLINO-ANDROSTANE DERIVATIVES | AKZO NOBEL N.V. (NL) | 1996-12-05 | — | — | WO | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199854-A1 | Process for the preparation of n-substituted 2-cyanopyrrolidines | CCND3, CBR3, CCNB3 | SLC6A2 3027/4885SLC6A4 1991/4885SLC6A3 1215/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SLC6A2 298/4885SLC6A4 741/4885SLC6A3 570/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SLC6A2 298/4885SLC6A4 741/4885SLC6A3 570/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | SLC6A2 1160/4885SLC6A4 2040/4885SLC6A3 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.